Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Study protocol

Personalised informed choice on evidence and controversy on mammography screening: study protocol for a randomized controlled trial

Authors: Anna Roberto, Cinzia Colombo, Giulia Candiani, Livia Giordano, Paola Mantellini, Eugenio Paci, Roberto Satolli, Mario Valenza, Paola Mosconi

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

In Italy women aged 50–69 are invited for a population-based breast cancer (BC) screening. Physicians, policy makers and patients associations agree on the need to inform women about the benefits and harms in order to permit an informed decision. Decision aids (DA) are an effective way to support people in their decisions about health. This trial aims to assess women’s informed choices, according to their health literacy and values, on participating or not in BC screening for the first time. Benefits, harms and controversies are presented.

Methods/design

The impact of the DA will be evaluated in a randomized controlled trial with a two-week follow-up. Women will be randomized via web to DA or a standard brochure. We will invite 8160 women, to obtain a final sample of 816 women. The primary outcome will be informed choice, measured on the basis of knowledge, attitudes and intentions on BC screening. Secondary outcomes are participation rate, satisfaction on information and decisional conflict.

Discussion

The web DA will be open-source and implemented on BC screenings and its efficacy for increasing informed choice will be tested. This model could be applied to other healthcare settings, cancer screenings, and public health programs.

Trial registration

The protocol for this trial was registered with the Clinicaltrials.​gov registry on March 16, 2017: NCT03097653.
Literature
1.
Armaroli P, Villain P, Suonio E, Almonte M, Anttila A, Atkin WS, et al. European code against cancer, 4th edition: cancer screening. Cancer Epidemiol. 2015 Dec;39(Suppl 1):S139–52.CrossRefPubMed
2.
3.
4.
Gotzsche PC, Jorgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013 Jun;4:CD001877.
5.
6.
Paci E, EUROSCREEN Working Group. Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. J Med Screen. 2012;19 Suppl 1:5–13.
7.
Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013 Jun 11;108(11):2205–40.CrossRefPubMedPubMedCentral
8.
Hersch J, Jansen J, Irwig L, Barratt A, Thornton H, Howard K, et al. How do we achieve informed choice for women considering breast screening? Prev Med. 2011 Sep;53(3):144–6.CrossRefPubMed
9.
Domenighetti G, D’Avanzo B, Egger M, Berrino F, Perneger T, Mosconi P, et al. Women’s perception of the benefits of mammography screening: population-based survey in four countries. Int J Epidemiol. 2003 Oct;32:816–21.CrossRefPubMed
10.
Domenighetti G, Grilli R, Maggi JR. Does provision of an evidence-based information change public willingness to accept screening tests? Health expect. 2000 Jun;3:145–150.
11.
Gotzsche PC, Hartling OJ, Nielsen M, Brodersen J, Jorgensen KJ. Breast screening: the facts--or maybe not. BMJ. 2009 Jan 27;338:b86.CrossRefPubMed
12.
Jorgensen KJ, Gotzsche PC. Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study. BMJ. 2004 Jan 17;328:148.CrossRefPubMedPubMedCentral
13.
Olsen O, Gotzsche PC. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2001;CD001877.
14.
Giordano L, von Karsa L, Tomatis M, Majek O, de Wolf C, Lancucki L, et al. Mammographic screening programmes in Europe: organization, coverage and participation. J Med Screen. 2012;19(Suppl 1):72–82.CrossRefPubMed
15.
Slaytor EK, Ward JE. How risks of breast cancer and benefits of screening are communicated to women: analysis of 58 pamphlets. BMJ. 1998 Jul 25;317:263–4.CrossRefPubMedPubMedCentral
16.
Duffy SW, Tabar L, Olsen AH, Vitak B, Allgood PC, Chen TH, et al. Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the breast screening Programme in England. J Med Screen. 2010;17:25–30.CrossRefPubMedPubMedCentral
17.
Hersch J, Jansen J, Barratt A, Irwig L, Houssami N, Howard K, et al. Women’s views on overdiagnosis in breast cancer screening: a qualitative study. BMJ. 2013 Jan 23;346:f158.CrossRefPubMedPubMedCentral
18.
19.
20.
21.
Stacey D, Legare F, Col NF, Bennett CL, Barry MJ, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2014 Jan;28:CD001431.
22.
Stacey D, Bennett CL, Barry MJ, Col NF, Eden KB, Holmes-Rovner M, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2011 Oct;5:CD001431.
23.
Mathieu E, Barratt AL, McGeechan K, Davey HM, Howard K, Houssami N. Helping women make choices about mammography screening: an online randomized trial of a decision aid for 40-year-old women. Patient Educ Couns. 2010 Oct;81(1):63–72.CrossRefPubMed
24.
Mathieu E, Barratt A, Davey HM, McGeechan K, Howard K, Houssami N. Informed choice in mammography screening: a randomized trial of a decision aid for 70-year-old women. Arch Intern Med. 2007 Oct 22;167:2039–46.CrossRefPubMed
25.
Hersch J, Barratt A, Jansen J, Irwig L, McGeechan K, Jacklyn G, et al. Use of a decision aid including information on overdetection to support informed choice about breast cancer screening: a randomised controlled trial. Lancet. 2015 Apr 25;385:1642–52.CrossRefPubMed
26.
27.
Legare F, Kearing S, Clay K, Gagnon S, D’Amours D, Rousseau M, et al. Are you SURE?: assessing patient decisional conflict with a 4-item screening test. Can Fam Physician. 2010 Aug;56:e308–14.PubMedPubMedCentral
28.
Metadata
Title
Personalised informed choice on evidence and controversy on mammography screening: study protocol for a randomized controlled trial
Authors
Anna Roberto
Cinzia Colombo
Giulia Candiani
Livia Giordano
Paola Mantellini
Eugenio Paci
Roberto Satolli
Mario Valenza
Paola Mosconi
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3428-9

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue

Research article

HPV and cofactors for invasive cervical cancer in Morocco: a multicentre case-control study

Research article

Preoperative cholesterol level as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with cyto-reductive nephrectomy

Study protocol

Understanding why cancer patients accept or turn down psycho-oncological support: a prospective observational study including patients’ and clinicians’ perspectives on communication about distress

Research article

Radiofrequency ablation for liver metastases in patients with gastric cancer as an alternative to hepatic resection

Research article

Diagnostic accuracy of 18F–FDG PET/CT and MR imaging in patients with adenoid cystic carcinoma

Research article

Precision oncology using a limited number of cells: optimization of whole genome amplification products for sequencing applications
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits